15 Jun 2022 --- The move by the US Senate Health, Education, Labor and Pensions Committee (HELP) to pass the Food and Drug Administration Safety and Landmark Advancement (FDASLA) Act was met with disappointment by industry organizations, which have branded the legislation as “dangerous” and “unwise.”
